Suguru Okami

701 total citations
26 papers, 446 citations indexed

About

Suguru Okami is a scholar working on Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Suguru Okami has authored 26 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 8 papers in Endocrinology, Diabetes and Metabolism and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Suguru Okami's work include Potassium and Related Disorders (10 papers), Diabetes Treatment and Management (8 papers) and Heart Failure Treatment and Management (5 papers). Suguru Okami is often cited by papers focused on Potassium and Related Disorders (10 papers), Diabetes Treatment and Management (8 papers) and Heart Failure Treatment and Management (5 papers). Suguru Okami collaborates with scholars based in Japan, Germany and Switzerland. Suguru Okami's co-authors include Toshitaka Yajima, Shun Kohsaka, Naohiko Kohtake, Eiichiro Kanda, Naoki Kashihara, Johan Bodegård, Marcus Thuresson, Takashi Kadowaki, Issei Komuro and Anna Norhammar and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Suguru Okami

24 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suguru Okami Japan 11 210 128 122 63 54 26 446
Giuseppe Cacciatore Italy 17 168 0.8× 130 1.0× 743 6.1× 34 0.5× 72 1.3× 57 1.1k
Yinggan Zheng Canada 15 108 0.5× 53 0.4× 377 3.1× 22 0.3× 71 1.3× 45 606
Yu‐Ling Yu China 15 121 0.6× 41 0.3× 169 1.4× 18 0.3× 65 1.2× 79 950
Dana Pop Romania 14 132 0.6× 45 0.4× 424 3.5× 19 0.3× 62 1.1× 143 743
Eliot Peyster United States 12 42 0.2× 146 1.1× 382 3.1× 44 0.7× 95 1.8× 27 629
Toru Kondo Japan 15 83 0.4× 99 0.8× 473 3.9× 23 0.4× 89 1.6× 141 888
M. Reza Skandari United States 14 209 1.0× 49 0.4× 26 0.2× 57 0.9× 38 0.7× 23 677
Francesca Palano Italy 13 116 0.6× 38 0.3× 475 3.9× 26 0.4× 59 1.1× 28 590
Ali Agha United States 13 48 0.2× 43 0.3× 258 2.1× 32 0.5× 74 1.4× 37 539

Countries citing papers authored by Suguru Okami

Since Specialization
Citations

This map shows the geographic impact of Suguru Okami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suguru Okami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suguru Okami more than expected).

Fields of papers citing papers by Suguru Okami

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suguru Okami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suguru Okami. The network helps show where Suguru Okami may publish in the future.

Co-authorship network of co-authors of Suguru Okami

This figure shows the co-authorship network connecting the top 25 collaborators of Suguru Okami. A scholar is included among the top collaborators of Suguru Okami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suguru Okami. Suguru Okami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yano, Yuichiro, Suguru Okami, Hiroshi Kanegae, et al.. (2025). Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan. Diabetes Obesity and Metabolism. 27(7). 3714–3724.
3.
Sato, Atsuhisa, Daloha Rodríguez-Molina, Satoshi Yamashita, et al.. (2024). Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan—A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform. Journal of Clinical Medicine. 13(17). 5107–5107. 7 indexed citations
4.
Okami, Suguru, Christoph Ohlmeier, Makiko Takeichi, et al.. (2024). Vericiguat Use in Patients with Heart Failure in Real-World Settings during the First Year after the Drug Authorization in Japan. Journal of Clinical Medicine. 13(11). 3222–3222. 4 indexed citations
5.
Okami, Suguru, M. Cecilia Aguila, Zuzana Mohrová, et al.. (2024). Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in Japan. Scientific Reports. 14(1). 2 indexed citations
6.
Kanda, Eiichiro, Suguru Okami, Shun Kohsaka, et al.. (2022). Machine Learning Models Predicting Cardiovascular and Renal Outcomes and Mortality in Patients with Hyperkalemia. Nutrients. 14(21). 4614–4614. 8 indexed citations
7.
Norhammar, Anna, Johan Bodegård, Jan W. Eriksson, et al.. (2022). Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries. Diabetes Obesity and Metabolism. 24(7). 1277–1287. 23 indexed citations
8.
Kohsaka, Shun, et al.. (2022). Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. Journal of Clinical Medicine. 11(19). 5828–5828. 7 indexed citations
9.
Kohsaka, Shun, Suguru Okami, Eiichiro Kanda, Naoki Kashihara, & Toshitaka Yajima. (2021). Cardiovascular and Renal Outcomes Associated With Hyperkalemia in Chronic Kidney Disease: A Hospital-Based Cohort Study. SHILAP Revista de lepidopterología. 5(2). 274–285. 16 indexed citations
10.
Okami, Suguru, et al.. (2021). Multiple objective metaheuristics for feature selection based on stakeholder requirements in credit scoring. Decision Support Systems. 155. 113714–113714. 17 indexed citations
11.
Okami, Suguru, et al.. (2021). Comparison of Profit-Based Multi-Objective Approaches for Feature Selection in Credit Scoring. Algorithms. 14(9). 260–260. 4 indexed citations
12.
13.
Kanda, Eiichiro, Naoki Kashihara, Shun Kohsaka, Suguru Okami, & Toshitaka Yajima. (2020). Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan. Kidney Medicine. 2(6). 742–752.e1. 19 indexed citations
14.
Birkeland, Kåre I., Johan Bodegård, Jan W. Eriksson, et al.. (2020). Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes Obesity and Metabolism. 22(9). 1607–1618. 146 indexed citations
15.
Kashihara, Naoki, Shun Kohsaka, Eiichiro Kanda, Suguru Okami, & Toshitaka Yajima. (2019). Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan. Kidney International Reports. 4(9). 1248–1260. 61 indexed citations
16.
17.
Okami, Suguru, et al.. (2017). Credit decision tool using mobile application data for microfinance in agriculture. 4714–4721. 2 indexed citations
18.
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giuseppe Cacciatore Breakdown of academic impact, for papers by Yinggan Zheng Breakdown of academic impact, for papers by Yu‐Ling Yu Breakdown of academic impact, for papers by Dana Pop Breakdown of academic impact, for papers by Eliot Peyster Breakdown of academic impact, for papers by Toru Kondo Breakdown of academic impact, for papers by M. Reza Skandari Breakdown of academic impact, for papers by Francesca Palano Breakdown of academic impact, for papers by Ali Agha
Rankless by CCL
2026